迈克生物：关于2025年第三季度计提信用及资产减值准备的公告

Core Viewpoint - The company announced a provision for credit and asset impairment to accurately reflect its financial status and asset value as of September 30, 2025, amounting to 20.6495 million yuan [1] Group 1 - The company made the provision based on the principles outlined in the "Enterprise Accounting Standards" and the "Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock Exchange" [1] - The provision is intended to account for potential credit and asset impairments within the consolidated financial statements [1] - The amount of the impairment provision for the third quarter of 2025 is 20.6495 million yuan [1]